DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs

• Egile Nagusiak: Masahiro Ohara (Egilea), Tetsuya Nagata (Egilea), Rintaro Iwata Hara (Egilea), Kie Yoshida-Tanaka (Egilea), Nozomi Toide (Egilea), Kazunori Takagi (Egilea), Kazuki Sato (Egilea), Tomoya Takenaka (Egilea), Masanori Nakakariya (Egilea), Kenichi Miyata (Egilea), Yusuke Maeda (Egilea), Kazuko Toh (Egilea), Takeshi Wada (Egilea), Takanori Yokota (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Antisense oligonucleotides (ASOs) are a therapeutic modality for incurable diseases. However, systemic injection of gapmer-type ASOs causes class-related toxicities, including prolongation of activated partial thromboplastin time (aPTT) and thrombocytopenia. We previously reported that cholesterol-c...